 |
| Issue 12, 30 September 2007
|
Dear Shareholders
Welcome to the latest edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments.
If you would like any further information, please contact us.
Regards
John Priest - CEO |
|
|
|
|
|
 |
Apollo Scientific Advisory Board Member to Head World’s Largest Stem Cell Research Institute
One of Apollo’s Advisory Board members, the Australian scientist Dr Alan Trounson, has been appointed as president of the California Institute for Regenerative Medicine (CIRM) in San Francisco.
With a budget totalling US$3 billion, CIRM is the largest source of funding for stem cell research in the world.
Dr Trounson, 61, was a pioneer of in-vitro fertilisation (IVF) and associated reproductive technologies in humans and instrumental in the development of human embryonic stem cells for use in medical research. Alan was the founding CEO of the Australian Stem Cell Centre, established in 2002, and is currently director of the Monash Immunology and Stem Cell Laboratories at Monash University in Melbourne.
|
|
|
|
Apollo creates first commercial hcx™ version of key stem cell factor
Apollo has produced the world’s first commercially available human cell expressed version of a key component of human stem cell research – a protein called Fibroblast Growth Factor 2 (FGF-2). FGF-2, also known as FGF basic, is widely used for stem cell research because it has versatile roles. In combination with other proteins, FGF-2 can maintain stem cells in an undifferentiated state and can also play a role in forming these undifferentiated stem cells into bone, skin or connective tissue cells which can be used to treat patients with diseases such as psoriasis and osteoarthritis. |
|
Advancing Apollo’s human proteins patent position in four key areas: inflammation, cancer, metabolism and regeneration/stem cells
Apollo is strengthening its position in human cell expressed (hcx™) proteins by taking 35 of its key human proteins to national phase patenting applications around the world.
Apollo is also focusing its protein development in the key areas of regeneration (stem cells), inflammation, cancer and metabolism, now that it has put in place a broad platform of more than 100 products. |
|
Cost of arthritis soars, according to new study
A new study has found that there has been a rapid increase in the impact of arthritis on individuals, carers and taxpayers to the tune of $24 billion annually. While the study’s results – released in August by Arthritis Australia – are alarming, the good news is that investment in prevention and treatment is highly cost-effective.
The findings highlighted the importance of Apollo's research into developing a drug that can both reduce the pain of arthritis and be taken in tablet form rather than injection, further reducing the health costs of treatment. |
|
| Click here to subscribe |
 |
| www.apollolifesciences.com |